Articles |
From the Department of Internal Medicine, Faculty of Medicine, University of Innsbruck, Innsbruck, Austria.
Correspondence to Univ. Prof. Dr. C. J. Wiedermann, Department of Internal Medicine/Intensive Care Medicine, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria.
Abstract Mesenchymal cell migration and replication are central biologic events involved in atherosclerosis and lung and hepatic fibrosis. Tissue repair and fibrosis are thought to be regulated by growth regulatory molecules, comprising both stimulators and inhibitors of mesenchymal cell functions, including platelet-derived growth factor (PDGF), transforming growth factor-ß (TGF-ß), fibroblast growth factors, and several neuropeptides such as substance P. Secretoneurin (SN), a novel 33-amino acid neuropeptide derived from secretogranin II (chromogranin C), is widely distributed in the central and peripheral nervous and neuroendocrine systems, including afferent C-fibers, and can be released in the periphery by capsaicin. Recently, we reported that SN triggers the selective migration of human monocytes and fibroblasts in vitro, implicating its involvement in inflammatory responses. We report herein that SN stimulates specific migration (maximal response at 10-10 M) of cultured arterial smooth muscle cells (SMCs), originating from rat thoracic aorta, and initiates DNA synthesis and SMC growth (BrdU incorporation, MTT test) with a maximum at 10-8 M SN to a similar extent as observed by PDGF. Both functional activities of SN were inhibited by specific anti-SN immunoglobulins (dilution, 1:1000), and furthermore, a trypsinized SN peptide (10-8 M) was unable to provoke biologic effects. Our studies suggest that SN functions as a regulatory peptide to modulate SMC migration and proliferation, which in conjunction with other factors could serve to aggravate and accelerate the development of atherosclerotic or restenotic lesions at sites of vascular injury.
Key Words: secretoneurin smooth muscle cells migration proliferation
This article has been cited by other articles:
![]() |
P. Liu, C. Zhang, J. B. Feng, Y. X. Zhao, X. P. Wang, J. M. Yang, M. X. Zhang, X. L. Wang, and Y. Zhang Cross Talk Among Smad, MAPK, and Integrin Signaling Pathways Enhances Adventitial Fibroblast Functions Activated by Transforming Growth Factor-{beta}1 and Inhibited by Gax Arterioscler Thromb Vasc Biol, April 1, 2008; 28(4): 725 - 731. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Troger, A. Doblinger, J. Leierer, A. Laslop, E. Schmid, B. Teuchner, M. Opatril, W. Philipp, L. Klimaschewski, K. Pfaller, et al. Secretoneurin in the Peripheral Ocular Innervation Invest. Ophthalmol. Vis. Sci., February 1, 2005; 46(2): 647 - 654. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Schirger, J. A. Grantham, I. J. Kullo, M. Jougasaki, P. W. Wennberg, H. H. Chen, O. Lisy, V. Miller, R. D. Simari, and J. C. Burnett Jr. Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition J. Am. Coll. Cardiol., March 1, 2000; 35(3): 796 - 801. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |